openPR Logo
Press release

Ewing Sarcoma Therapeutics - Pipeline Analysis Celgene, Novartis, Pfizer, MacroGenics, Inc.

12-13-2018 07:07 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from: P&S Intelligence

Ewing Sarcoma Therapeutics - Pipeline Analysis Celgene,

Ewing sarcoma pipeline comprises approximately 29 drug candidates in different stages of development.

Ewing sarcoma is a condition in which formation of cancer or tumor takes place in bones and soft tissues. The symptoms associated with Ewing sarcoma include pain as well as swelling in the chest, back, legs, pelvis and arms, lumps in arms, bone fracture, weight loss, loss of appetite, fatigue, malaise, etc.

Download free report Sample at: https://www.psmarketresearch.com/market-analysis/ewing-sarcoma-therapeutics-pipeline-analysis/report-sample

*Major companies collaborate for the development of Ewing sarcoma pipeline

The research also found that various companies are engaged in collaborations for Ewing sarcoma. In April 2014, NanoSmart Pharmaceuticals Inc. and NanoValent Pharmaceuticals Inc., entered into a research collaboration agreement to find out the feasibility of jointly developing an ANA-conjugated liposomal doxorubicin nanoparticle for the treatment of ovarian cancer and other solid tumors.

Browse report at: https://www.psmarketresearch.com/market-analysis/ewing-sarcoma-therapeutics-pipeline-analysis

*Novel and patented technologies for Ewing sarcoma pipeline

Novel technologies are being used for Ewing sarcoma drug candidates. MacroGenics Inc., has been using Fc Optimization platform for the development of their drug candidates.

Pre-Purchase Inquiry at: https://www.psmarketresearch.com/send-enquiry?enquiry-url=ewing-sarcoma-therapeutics-pipeline-analysis

Some of the key players developing Ewing sarcoma therapeutics include Celgene Corporation, Pfizer Inc., and Novartis AG, and others.

About P&S Intelligence

P&S Intelligence, a brand of P&S Market Research, is a provider of market research and consulting services catering to the market information needs of burgeoning industries across the world. Providing the plinth of market intelligence, P&S as an enterprising research and consulting company, believes in providing thorough landscape analyses on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness.

Contact:
P&S Intelligence
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Ewing Sarcoma Therapeutics - Pipeline Analysis Celgene, Novartis, Pfizer, MacroGenics, Inc. here

News-ID: 1437011 • Views: 816

More Releases from P&S Intelligence

AR and VR Market Drivers, Restraints, Opportunities, and Trends in Coming Years
The augmented reality (AR) and virtual reality (VR) market is expected to witness a strong CAGR, of 42.9%, during the forecast period (2020–2030), owing to the soaring focus of vendors on price reduction, growing penetration of tablet computers and smartphones, and surging adoption of AR and VR technologies in the healthcare, gaming, tourism, education, and entertainment industries. According to P&S Intelligence, the market was valued at $37.0 billion in 2019
RF Transceiver Market Drivers, Restraints, Opportunities, and Trends in Coming Y …
The major factors responsible for the growth of the radiofrequency (RF) transceiver market are the increasing demand for smartphones and rising penetration of the internet of things (IoT) technology. Due to this, the revenue generated by the market players, which stood at $3,892.1 million in 2019, is projected to grow at a 0.8% CAGR during 2020–2030 (forecast period), to reach $3,384.5 million by 2030. The RF transceiver is an important
HVAC Market Drivers, Restraints, Opportunities, and Trends in Coming Years
Factors such as the growing construction sector, increasing government initiatives to support the installation of heating, ventilation, and air conditioning (HVAC) systems, surging demand for energy-efficient systems, and rising global surface temperature are expected to drive the growth of the HVAC market at a 4.8% CAGR during the forecast period (2020–2030). With this growth rate, the market size will increase from $240.8 billion in 2019 to $358.1 billion by 2030. Get
U.A.E HVAC Market Recent Trends, Developments, Challenges and Opportunities
A surge in construction activities in the transportation sector of the U.A.E. has led to the widescale adoption of heating, air conditioning, and ventilating (HVAC) systems in the country. The gulf country is spending hefty amounts on the construction of airports and expansion of railway infrastructure. These new facilities adopt HVAC equipment to offer better amenities. For example, the U.A.E. government launched "Route 2020" in 2018, to extend the Red

All 5 Releases


More Releases for Ewing

Ewing Sarcoma Market (2019-2028) Overview with Size, Patients Population, Total …
Ewing Sarcoma Market Synopsis: Global Ewing Sarcoma Market Insights, Epidemiology and Market Forecast studies the present scenario of market (with the base year being 2018), Key Cross Competition, and the growth prospects of global Ewing Sarcoma market for 2018-2028 definition of Ewing Sarcoma: Ewing sarcoma is a malignant small, round, blue cell tumor. It is a disease in which cancer cells are found in the bone or in soft tissue. The most common
Research Focused On the Ewing Sarcoma Treatment Market Size & Share, Growth, Tre …
The report "Ewing Sarcoma Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 – 2025 ", has been prepared based on an in-depth market analysis with inputs from industry experts. The objectives of this study are as follows: To define, describe, and forecast the "Ewing Sarcoma Treatment" market by type, application, component, delivery model, end user, and region To provide detailed information regarding major factors influencing market growth (drivers,
Ewing Sarcoma Global Clinical Trials Review H2 2017
Summary: ReportsWeb.com published “Ewing Sarcoma Global Clinical Trials” from its database. The report reviews top companies involved and enlists all trials pertaining to the company. Report provides latest news for the past three months. Original Content: "Ewing Sarcoma Industry Outlook to 2022-Market Forecasts for Liquefied Natural Gas (LNG), Oil Storage, Pipelines and Gas Processing", is a comprehensive report on midstream oil and gas industry in Algeria. The report provides details such as name,
Ewing Sarcoma Global Clinical Trials Status, Region and Phase Review, H2, 2017
To Understand the Pharmaceutical Industry Status worldwide, Market Research Hub (MRH) has included the latest Forecast report titled “Ewing Sarcoma Global Clinical Trials Review, H2, 2017, provides an overview of Ewing Sarcoma clinical trials scenario. This report provides top line data relating to the clinical trials on Ewing Sarcoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers
Ewing sarcoma has a Promising Pipeline with approximately 29 Drug Candidates
Ewing sarcoma pipeline comprises approximately 29 drug candidates in different stages of development. Ewing sarcoma is a condition in which formation of cancer or tumor takes place in bones and soft tissues. The symptoms associated with Ewing sarcoma include pain as well as swelling in the chest, back, legs, pelvis and arms, lumps in arms, bone fracture, weight loss, loss of appetite, fatigue, malaise, etc. Explore Report Description at: www.psmarketresearch.com/market-analysis/ewing-sarcoma-therapeutics-pipeline-analysis Major companies
NantCell receives FDA orphan drug status for Ganitumab Monoclonal Antibody Thera …
NantCell, Inc., part of the NantWorks ecosystem of companies, has been granted orphan drug designation from US Food and Drug Administration (FDA) for the company’s Ganitumab, Insulin Growth Factor-1R (IGF-1R) Monoclonal Antibody Therapy for the treatment of Ewing Sarcoma. Ganitumab is a fully human monoclonal antibody directed against IGF-1R that is being investigated in a Phase III human clinical trial. Mechanism of action of the monoclonal antibody is described as IGF-1R